Presentations

  The Critical Issues 2013 faculty was composed of more than
60 outstanding faculty members from more than 10 countries
around the world. More than 60 lectures were presented during
Critical Issues 2013.

Review any of the authorized presentations.
   
   
Friday, June 21
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
07:45 – 08:15
Registration and Coffee
   
08:15 – 08:30
Introduction     E. Verhoeven 
   
8:30 – 10:30
Session 1: The practical session – part I
Chairmen: E. Verhoeven, M. Thompson    
Commentator: J. Fernandes e Fernandes

   
08:30 – 08:36
AAA is progressive disease: implications for patient and technique selection AAA is progressive disease: implications for patient and technique selection      J. Brennan
   
08:37 – 08:43
Angulated necks: implications with regard to oversizing and when not to treat by EVAR? Angulated necks: implications with regard to oversizing and when not to treat by EVAR?     F. Moll
   
08:44 – 08:50
Addressing the severely angulated neck with EVAR Addressing the severely angulated neck with EVAR     J. Hardman
   
08:51 – 08:57
Low profile grafts will expand indications or result in EVAR treatment of non-suitable patients? Low profile grafts will expand indications or result in EVAR treatment of non-suitable patients?     D. Adam
   
08:58 – 09:04
Low profile grafts: are there patients that we should not treat even if we can get the grafts in? Low profile grafts: are there patients that we should not treat even if we can get the grafts in?     M. Tenholt 
   
09:04 – 09:30
Discussion
   
09:30 – 09:36
The evidence for pre-operative embolization of aortic branches prior to EVAR     R. Mc Williams
   
09:37 – 09:43
Interpretation of the CAESARS trial: when should we (if at all) treat small AAA? Interpretation of the CAESARS trial: when should we (if at all) treat small AAA?     P. Cao
   
09:44 – 09:50
Which neck length is required in the arch and which devices can accommodate the arch? Which neck length is required in the arch and which devices can accommodate the arch?     D. Böckler
   
09:51 – 09:57
Long-term results of iliac branched endografts: the role of different hypogastric stent-grafts? Long-term results of iliac branched endografts: the role of different hypogastric stent-grafts?     F. Verzini
   
09:58 – 10:04
Treatment of traumatic thoracic injury, lessons learned from the past and a look into the future Treatment of traumatic thoracic injury, lessons learned from the past and a look into the future     M. Lachat
   
10:04 – 10:30
Discussion
   
10:30 – 11:00
Break
   
11:00 – 12:15
Session 2: The modesty session – EVAR update and new concepts
Chairmen: M. Malina, W. Ritter
Commentator: D. Raithel

11:00 – 11:06
How valid are randomized EVAR trials in the face of current and new device technology? How valid are randomized EVAR trials in the face of current and new device technology?     J. Blankensteijn
   
11:07 – 11:13
New EVAR techniques or devices: what do we need to demonstrate efficacy and durability?  New EVAR techniques or devices: what do we need to demonstrate efficacy and durability?     M. Thompson
   
11:14 – 11:20
Lessons learned from the ENGAGE registry: how far can we go with standard EVAR? Lessons learned from the ENGAGE registry: how far can we go with standard EVAR?     H. Verhagen
   
11:21 – 11:27
Lessons learned from the GREAT registry on C3 Excluder  Lessons learned from the GREAT registry on C3 Excluder     E. Verhoeven
   
11:27 – 11:35
Discussion
   
11:35 – 11:41
The Cordis INCRAFT AAA Endograft: Next generation technology that combines low profile with ease of use The Cordis INCRAFT AAA Endograft: Next generation technology that combines low profile with ease of use     B. Gehringhoff
   
11:42 – 11:48
Sealing is believing. How an innovative sealing (TRIVASCULAR) changes the approach to EVAR? Sealing is believing. How an innovative sealing (TRIVASCULAR) changes the approach to EVAR?     M. Tenholt
   
11:49 – 11:55
The benefits of treating complex AAA anatomy on label with Aorfix? The benefits of treating complex AAA anatomy on label with Aorfix?     N. Mosquera
   
11:56 – 12:02
NELLIX provides an interesting new concept. What is next?     A. Holden
   
12:03 – 12:08
Aptus endoanchors: as a rescue or to expand indications of standard EVAR?     J-P. de Vries
   
12:08 – 12:15
Discussion
   
   
12:15 – 13:15 Session 3: The selection session in pararenal AAA
Chairmen: J. Brennan, J. Blankensteijn    
Commentator: J. Busquet

12:15 – 12:21
The literature evidence in short necked AAA: what to propose first? The literature evidence in short necked AAA: what to propose first?     I. Loftus
   
12:22 – 12:28
Which solution for which patient: how to find the best solution for each individual patient? Which solution for which patient: how to find the best solution for each individual patient?     M. Austermann
   
12:29 – 12:35
Update on the fenestrated Anaconda Update on the fenestrated Anaconda     J. Brunkwall
   
12:36 – 12:42
Open chimney for juxta renal AAA Open chimney for juxta renal AAA     E. Ducasse
   
12:43 – 12:49
Pitfalls and technical tips for CHEVAR and SNEVAR Pitfalls and technical tips for CHEVAR and SNEVAR     A. Assadian
   
12:50 – 12:56
Technique to make home-fenestrated grafts  Technique to make home-fenestrated grafts     J. Ricotta
   
12:57 – 13:03
New concept inner branch for visceral vessels: does it work? For which patients?     M. Ferreira
   
13:03 – 13:15
Discussion
   
13:15 – 14:30
Lunch
   
14:30 – 16:15 Session 4: Top gun session – TAAA treatment
Chairmen: R. Mc Williams, F. Vermassen    
Commentator: T. Mastracci

14:30 – 14:36
Results of endovascular repair of TAAA: how to select the right patients? Which patients should not be treated at all?     R. Greenberg
   
14:37 – 14:43
Which TAAA patients should be treated with open techniques and which patients should not be treated at all?     M. Jacobs
   
14:44 – 14:50
Are sandwich grafts in TAAA a real alternative to custom made branched devices?      R. Kolvenbach
   
14:51 – 14:57
Chimneys and in-situ grafts in the arch     M. Malina
   
14:57 – 15:22
Discussion
   
15:22 – 15:28
The arch branched device: results improve quickly on the short term but what to expect from the longer term and which alternative techniques are possible? The arch branched device: results improve quickly on the short term but what to expect from the longer term and which alternative techniques are possible?     K. Ivancev
   
15:29 – 15:35
Apical approach for TEVAR: a fine and safe solution in difficult cases or just another gimmick?     T. Kölbel
   
15:36 – 15:42
Total arch repair with a novel branched graft. In which patients can we use this device? Total arch repair with a novel branched graft. In which patients can we use this device?     Q. Lu
   
15:43 – 15:49
Frozen elephant trunk with the Vascutek Thoraflex Prosthesis     M. Pichlmaier
   
15:50 – 15:56
The Medtronic LSA branch Valiant thoracic device: which patients do we target? The Medtronic LSA branch Valiant thoracic device: which patients do we target?     M. Thompson
   
15:56 – 16:15
Discussion
   
16:15 – 16:45
Break
   
16:45 – 18:15
Session 5: The decision session about Type B dissections
Chairmen: T. Resch, P. Taylor    
Commentator: M. Ferreira

16:45 – 16:51
Comparison of endovascular and medical therapy in uncomplicated Type B dissection: lessons learned Comparison of endovascular and medical therapy in uncomplicated Type B dissection: lessons learned     Q. Lu
   
16:52 – 16:58
The long term results of Instead underline that uncomplicated Type B dissections should be treated early with TEVAR. Are there patients that should NOT be treated?     C. Nienaber 
   
16:59 – 17:05
Arguments to treat uncomplicated acute Type B dissection Arguments to treat uncomplicated acute Type B dissection     M. Thompson
   
17:06 – 17:12
Adsorb was totally underpowered, but still shows that acute Type B dissection should be treated Adsorb was totally underpowered, but still shows that acute Type B dissection should be treated     J. Brunkwall
   
17:13 – 17:18
Predictors of success following TEVAR for chronic dissection Predictors of success following TEVAR for chronic dissection     P. Taylor
   
17:19 – 17:25
Fenestrated grafts for chronic Type B dissections: the Cleveland Clinic approach     R. Greenberg
   
17:25 – 18:15
Discussion
   
   
19:00 – 20:00
Reception
   
20:00 – 23:00
Congress dinner and get together
Old Town Hall Nuremberg (walking distance)
   
   
Saturday, June 22
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
 
08:00 – 08:15
Welcome and coffee
   
08:15 – 10:00
Sesssion 6: The practical session – part II
Follow-up and complications session
Chairmen: S. Haulon, D. Raithel    
Commentator: J. Fernandes e Fernandes
   
08:15 – 08:21
Renal outcome after FEVAR/BEVAR and CHEVAR: what can we really expect?     G. Hamilton
   
08:22 – 08:28 
Long term results with fenestrated grafts with covered stents for the fenestrations  Long term results with fenestrated grafts with covered stents for the fenestrations     I. Tielliu
   
08:29 – 08:35 Improved results with the new Atrium V12?  Improved results with the new Atrium V12?     E. Verhoeven
   
08:36 – 08:42 EVAR follow-up: is it time to discuss individualized follow-up schemes based on preoperative anatomy and high quality completion angiography? EVAR follow-up: is it time to discuss individualized follow-up schemes based on preoperative anatomy and high quality completion angiography?     G. Pratesi
   
08:43 – 08:49 Follow-up without CT: why and when? Follow-up without CT: why and when?     K. Oikonomou
   
08:50 – 08:56 Overview of endoleaks and diagnostic algorythm Overview of endoleaks and diagnostic algorythm     G. Maleux
   
08:57 – 09:03 How to treat endoleaks Type I and III     A. Holden
   
09:04 – 09:10
When and how to treat endoleaks Type II     R. Mc Williams
   
09:10 – 10:00
Discussion
   
10:00 – 10:30
Break
   
10:30 – 11:45
Session 7: The imaging session with the clash of the Titans
Chairmen: R. Mc Williams, T. Resch    
Commentator: W. Ritter

 10:30 – 10:36 Siemens flash presentation: new developments with Siemens     G. Nollert
   
10:37 – 10:43
Working flow with the new Artis Zeego Hybrid room in New York    N. Cayne
   
10:44 – 10:50
GE flash presentation: new developments with GE GE flash presentation: new developments with GE     M. Grimaud
   
10:51 – 10:57
The GE hybrid room changed my (working) life The GE hybrid room changed my (working) life     S. Haulon
   
10:58 – 11:04
How to build a hybrid room that works at once? How to build a hybrid room that works at once?     H. Eckstein
   
11:05 – 11:11
Dyna CT in the hybrid OR: how and when to use? Dyna CT in the hybrid OR: how and when to use?     M. Steinbauer
   
11:12 – 11:18
Future imaging techniques in aortic pathologies and clinical implications     R. Clough
   
11:18 – 11:45
Discussion
   
11:45 – 13:00
Session 8: The acute session and the difficult road to off-the-shelf grafts
Chairmen: P. Taylor, W. Wisselink    
Commentator: S. Haulon

 11:45 – 11:51 The Ajax trial results: implications for the future The Ajax trial results: implications for the future     W. Wisselink
   
11:52 – 11:58
Set-up for endovascular acute AAA treatment in Malmö: how to treat more than 90% of patients by endovascular means     M. Malina
   
11:59 – 12:05
Acute pararenal AAA: the homemade surgeon-modified fenestrated graft, no future?     J. Ricotta
   
12:05 – 12:20
Discussion
   
12:20 – 12:26
Off-the-shelf TAAA devices-is one device enough? Off-the-shelf TAAA devices-is one device enough?      P. Kasprzak
   
12:27 – 12:33
The Ventana off-the-shelf graft for pararenal AAA The Ventana off-the-shelf graft for pararenal AAA     A. Holden
   
12:34 – 12:40
Results with the new Cook p-branch fenestrated device for pararenal AAA Results with the new Cook p-branch fenestrated device for pararenal AAA     T. Resch
   
12:40 – 13:00
Discussion
   
13:00 – 14:00
Lunch
   
14:00 – 15:30
Session 9: The blast from the past session: come on, give us a follow up
Chairmen: E. Verhoeven, R. Greenberg    
Commentator: T. Resch

14:00 – 14:06
Late paraplegia after endovascular TAAA repair Late paraplegia after endovascular TAAA repair     F. Vermassen
   
14:07 – 14:13 Staged TAAA repair? Does it really help, if yes why?     T. Mastracci
   
14:14 – 14:20 Extra branch for spinal cord perfusion? Do the results prove us right? Extra branch for spinal cord perfusion? Do the results prove us right?     P. Kasprzak
   
14:21 – 14:27 Monitoring spinal cord function during TAAA branched grafting, mandatory? Monitoring spinal cord function during TAAA branched grafting, mandatory?     G.W.H. Schurink
   
14:28 – 14:34 Short neck in standard EVAR: does it really work? Long-term results?        J. Teßarek
   
14:35 – 14:41 EVAR in short/no necked RAAA? Outcome?     M. Malina
   
14:42 – 14:48 Distal fenestration for TAAA Type I: late extension of disease? Distal fenestration for TAAA Type I: late extension of disease?     V. Riambau
   
14:49 – 14:55 The renal side of the story: long term results     R. Greenberg
   
14:55 – 15:02
Robotic surgery in vascular surgery, an update     N. Cheshire
   
15:02 – 15:30
Discussion
   
15:30 
Adjourn
   
   
16:00
Buses leave for Siemens Erlangen/Forchheim
   
16:30 – 18:30
Visit Siemens factory
   
19:00 – 23.00 
Visit Vaults in Forchheim & Get together (Local beer & Food party)
   
   
  Download Programme Download Programme